Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Methotrexate
•
General Rheumatology
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
Related Questions
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
What is the maximum dose of leucovorin that you use with methotrexate?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
